JNJ 241220 128.00P (JNJ241220P128000) Stock Options, News & Quotes

US OptionsDetailed Quotes

JNJ241220P128000

Watchlist

0.00
0.000.00%

15min DelayClose Dec 20 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

RxSight Cut to Hold at Stifel on Competition Concerns
Seeking AlphaDec 20 10:43 ET
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Kevin TraversDec 20 10:29 ET
After GE's Spinoff Success, What's Next for Honeywell, FedEx
BarronsDec 20 02:00 ET
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
BenzingaDec 19 13:38 ET
Why Is Johnson & Johnson (JNJ) Among the Best Dividend Stocks to Invest In?
Yahoo FinanceDec 19 06:16 ET
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Kevin TraversDec 18 16:16 ET

Comments

Phil Dunn

13 hours ago

Review of the very harsh 3rd week Dec

Devastating Crash of $Novo-Nordisk A/S (NVO.US)$ and Strong Rebound of $NVIDIA (NVDA.US)$ on Black Friday.
I made a difficult but crucial decision on Friday to sell off losing positions at pre-market which were moving downtrend so badly like $Novo-Nordisk A/S (NVO.US)$ , $D.R. Horton (DHI.US)$ , $Huntington Ingalls Industries (HII.US)$ , $MarketAxess (MKTX.US)$ . Especially obesity drug giant NVO which collapsed 25% at pre-market after disappointing trial results o...

Powell says no hurry for Fed rate cuts, how will you adjust your investment strategy?

Ultratech

Yesterday 10:01

$Johnson & Johnson (JNJ.US)$
bottoming soon

KyleyW

Dec 16 12:06

$Johnson & Johnson (JNJ.US)$ how low can it drop? below 140? i wanted to enter

10xStockPicks

Dec 15 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...